Report
EUR 16.73 For Business Accounts Only

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS
Underlying
Aclaris Therapeutics

Aclaris Therapeutics is a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases. The company's commercial product, ESKATA (hydrogen peroxide) topical solution, 40% (w/w), or ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. The company has acquired RHOFADE (oxymetazoline hydrochloride) cream, 1%, or RHOFADE, which includes a license to certain intellectual property for RHOFADE, from Allergan Sales, LLC. RHOFADE has been approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

Provider
ValuEngine Inc
ValuEngine Inc

​ValuEngine Rating and Forecast Reports provide the most comprehensive and useful report available. ValuEngine's three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. ValuEngine provides coverage of over 5300 US stocks (which includes over 800 ADRs), all of which are updated daily after US market close.

 

ResearchPool Subscriptions

Get the most out of your insights

Get in touch